Bridge for Billions, one of the largest entrepreneurship networks worldwide that creates, designs, and manages innovation programs, has partnered with Elaj Group, Al Borg Medical Laboratories and Jadara Ventures to connect with ready-to-invest or pilot-ready startups in the MedTech sector to achieve their mission of democratizing innovative healthcare services by providing them at affordable prices. The initiative, Al Borg MedTech Accelerator, supports businesses based in the MENA region and Pakistan with a four-month incubation program and expert sessions.
Startups working in MedTech, Genomics, or AI based in the MENA region or Pakistan can apply until April 7th through this website. The accelerator program is equity-free and participants will have potential investment after graduation from Al Borg Laboratories. Also, the initiative will support the startups to scale in the region, as well as providing legal setup support and benefiting from Al Borg Facilities & Labs. Entrepreneurs will have weekly sessions and mentorship from experts and the opportunity to connect their startups with investors.
“Al Borg Diagnostics was established more than 20 years ago, aiming at enhancing population health via providing high quality medical diagnostic services in a timely, accurate, and efficient manner, using expertise and the most advanced technology”, says Dr. Ahmed Saeed, Chief Commercial Officer at Al Borg. “Believing that continuous development and innovation is the key that will shape the future of diagnostics, Al Borg Diagnostics is proud to announce the launch of a Healthcare Accelerator Program (Al Borg Medtech Accelerator) that will help boost these beliefs and to advance Life-Sciences in the region”, explains Saeed.
Al Borg MedTech Accelerator is aimed at full-time entrepreneurs with expertise in innovation challenges such as diagnosis, medical robotics and 3D printing, healthcare database management, medical IoT, medical AR & VR and medical AI, gamification and genomics. The initiative is looking for startups that want to scale-up by partnering up with a leading reference in the medical sector such as Elaj Group, and willing to dedicate 8 hours per week for the duration of the program; and mentors who want to support entrepreneurs through weekly mentoring as they work on their venture.
This partnership marks the launch of Bridge for Billions into the MENA region, where the organization is expanding its operations. To this date, Bridge for Billions has supported more than 1,700 entrepreneurs in over 80 countries. The company has worked with more than 100 organizations such as Coca-Cola, Accenture or BMW, and institutions such as the United Nations, in order to promote the creation of innovative solutions that benefit society.
About Bridge for Billions
Bridge for Billions, one of the largest entrepreneurship networks worldwide, creates, designs, and manages innovation programs that have benefited more than 1,700 entrepreneurs in over 80 countries. Its objective is to democratize access to entrepreneurship support, from university students to small business owners, with a common purpose: innovate to generate a positive change within their communities. Bridge for Billions, recognized by Forbes 30 Under 30 and Ashoka, has worked with more than 100 organizations such as Coca-Cola, Accenture or BMW, and institutions such as the United Nations, in order to promote the creation of innovative solutions that benefit society.
For more information, please visit https://bridgeforbillions.org/
Social Media: Facebook | Twitter | Instagram | LinkedIn
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
